Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Dexcom (DXCM) Research & Development (2016 - 2025)

Historic Research & Development for Dexcom (DXCM) over the last 17 years, with Q4 2025 value amounting to $148.2 million.

  • Dexcom's Research & Development rose 623.66% to $148.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $599.1 million, marking a year-over-year increase of 845.4%. This contributed to the annual value of $599.1 million for FY2025, which is 845.4% up from last year.
  • According to the latest figures from Q4 2025, Dexcom's Research & Development is $148.2 million, which was up 623.66% from $157.5 million recorded in Q3 2025.
  • In the past 5 years, Dexcom's Research & Development ranged from a high of $157.5 million in Q3 2025 and a low of $109.4 million during Q1 2021
  • In the last 5 years, Dexcom's Research & Development had a median value of $135.6 million in 2022 and averaged $132.9 million.
  • As far as peak fluctuations go, Dexcom's Research & Development surged by 6157.7% in 2021, and later plummeted by 2236.32% in 2022.
  • Dexcom's Research & Development (Quarter) stood at $149.8 million in 2021, then dropped by 22.36% to $116.3 million in 2022, then grew by 17.02% to $136.1 million in 2023, then grew by 2.5% to $139.5 million in 2024, then increased by 6.24% to $148.2 million in 2025.
  • Its last three reported values are $148.2 million in Q4 2025, $157.5 million for Q3 2025, and $148.2 million during Q2 2025.